How Long Is Long Enough? Rethinking mRNA for In Vivo CAR-T

• Addressing the in vivo CAR-T tradeoff between durable CAR expression and safety
• Using data from primary human T cells and in vivo models to explore mRNA expression
• Exploring how cap structures, UTR design, and poly(A) tail engineering can deliver what in vivo CAR-T demands: not peak height, but duration

Speakers:

Damien Zanker

Head of Clinical Manufacturing

Cartherics Pty Ltd

Davide De Lucrezia

Senior Vice President, Digital Innovation, Products & Marketing

TriLink BioTechnologies